Table I.
Patient characteristics at the time of initial treatment.
| Patient ID | Sex | Age (years) | ECOG | Primary site | Clinical TNM | Dose of RT (total/daily, Gy) | RT technique | Concurrent chemo (drugs) | Surgical pathology | Pathologic TNM |
|---|---|---|---|---|---|---|---|---|---|---|
| A | F | 81 | 1 | GE junction | T2N2M0 | 50.4/1.8 | 3D conformal | Carboplatin, paclitaxel | Adenocarcinoma | ypT1bN0M0 |
| B | M | 62 | 1 | Lower esophagus | T3N0M0 | 45.0/1.8 | 3D conformal | Carboplatin, paclitaxel | Adenocarcinoma | ypT1bN0M0 |
| C | M | 63 | 0 | Upper esophagus | T2N1M0 | 50.4/1.8 | 3D conformal | Carboplatin, paclitaxel | Adenocarcinoma | ypT2N1M0 |
| D | M | 76 | 0 | Mid-esophagus | T1bN0M0 | 64.8/1.8 | IMRT | Carboplatin, paclitaxel | Squamous | ypT1bN0M0 |
| E | M | 61 | 0 | Lower esophagus | T3N1M0 | 52.2/1.8 | 3D conformal | Carboplatin, paclitaxel | Adenocarcinoma | ypT2N0M0 |
| F | M | 76 | 1 | GE junction | T3N0M0 | 48.6/1.8 | IMRT | Carboplatin, paclitaxel | Adenocarcinoma | ypT3N2M0 |
| G | M | 74 | 0 | GE junction | T2N0M0 | 50.4/1.8 | 3D Conformal | Carboplatin, paclitaxel | Adenocarcinoma | ypT3N0M0 |
F, female; M, male; ECOG, Eastern Cooperative Oncology Group; GE, gastroesophageal; RT, radiotherapy; 3D, 3 dimensional; yp, pathological data following pre-operative chemoradiation.